US20060228394A1 - Ocular solutions - Google Patents
Ocular solutions Download PDFInfo
- Publication number
- US20060228394A1 US20060228394A1 US11/451,100 US45110006A US2006228394A1 US 20060228394 A1 US20060228394 A1 US 20060228394A1 US 45110006 A US45110006 A US 45110006A US 2006228394 A1 US2006228394 A1 US 2006228394A1
- Authority
- US
- United States
- Prior art keywords
- concentration
- ocular
- macrolide antibiotic
- composition
- treat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Ocular solutions containing at least one macrolide antibiotic and/or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions. The solution may contain a supratherapeutic concentration of agent(s) so that a therapeutic concentration of a topically administered solution accumulates in a diseased ocular structure sufficient to treat the disease. The agent(s) may be formulated with polymers or other components for extended or slow release to provide a substantially constant concentration over the course of treatment.
Description
- This application is a Continuation of U.S. patent application Ser. No. 10/752,124 filed Jan. 6, 2004 which is a Continuation-In-Part of U.S. patent application Ser. No. 10/667,161 filed Sep. 19, 2003, which is expressly incorporated by reference herein in its entirety.
- The invention is directed to ocular solutions containing macrolide antibiotics to provide anti-inflammatory and other beneficial effects.
- The eye is naturally bathed internally and externally by ocular fluids. The external portion of the eye is lubricated by lacrimal fluids (tears). The internal portion of the eye has two fluid-containing chambers: the anterior chamber contains the aqueous humor or aqueous, and the posterior chamber contains the vitreous humor or vitreous.
- Various conditions require the need to introduce fluids into or on the surface of the eye to replace or replenish naturally occurring fluids. The loss of naturally occurring ocular fluids may be due to normal aging, pathological conditions, surgical intervention, etc. For example, during ocular surgery, the vitreous is frequently removed and must thereafter be replaced. Commercially available irrigating solutions are often used to replace some or all of the vitreous, such as irrigating solutions infused to replace the vitreous removed during vitrectomy and thereby to maintain the shape of the globe. The composition and other properties of these solutions may affect the surgical outcome for the patient, for example, a solution may affect the clarity of the cornea and lens, which may result in decreased visual acuity. Additionally, swelling of the cornea during vitrectomy may be influenced by components of the irrigating solution. Other conditions such as dry eye disease result in decreased external lubrication, and topical solutions such as eye drops are often used to provide relief. Wash solutions are used topically to remove foreign material from the external surface of the eye and invasively to clear the cornea and other structures during surgery.
- Ocular solutions, for introduction into the eye and/or topical application, with improved properties are desirable. The invention describes such compositions and method of using the compositions.
- A substitute for an intraocular irrigating, wash, or volume replacement solution is disclosed. The solution contains a concentration in the range from about 1 ng/ml to about 200 μg/ml of a macrolide antibiotic and/or mycophenolic acid. This provides beneficial properties, such as reducing inflammation at a surgical site (anti-inflammatory effect), inhibiting cell migration and cell proliferation (anti-proliferative and anti-migratory effects), inhibiting the growth of new blood vessels at the site of an ocular tumor (anti-angiogenic effect), reducing the growth of bacteria, fungi, etc. (anti-microbial and anti-fungal effects). Its anti-inflammatory effect desirably occurs without an increase in intraocular pressure, which may occur when steroids are administered to control ocular inflammation. Such a composition may be used in patients undergoing ocular surgery such as cataract surgery, retinal repair, etc.
- The macrolide and/or mycophenolic acid can be added to a commercially available ocular solution, or can be formulated with an ocular solution. The macrolide antibiotic can be tacrolimus, cyclosporine, sirolimus, everolimus, ascomycin, erythromycin, azithromycin, clarithromycin, clindamycin, lincomycin, dirithromycin, josamycin, spiramycin, diacetylmidecamycin, tylosin, roxithromycin, ABT-773, telithromycin, leucomycins, and lincosamide. It can be formulated in an inert matrix, a capsule, a liposome, etc. It can be inserted, injected, or implanted within a specific site of the eye (e.g., within the lens capsule), or applied generally to clear or wash a surgical field.
- In one embodiment, the inventive ocular composition is administered to a patient undergoing cataract surgery. The solution, containing a concentration in the range from about 20 μg/ml to about 200 μg/ml (about 0.002%w/v to about 0.02%w/v) of a macrolide antibiotic and/or mycophenolic acid is introduced within the capsule of the lens after the diseased lens has been removed and before the replacement lens is inserted. Microspheres or microcapsules of the macrolide antibiotic and/or mycophenolic acid can be implanted within the capsule in an alternate embodiment. This can be used to reduce opacification of the posterior capsule, which is a common problem following cataract surgery.
- An implantable lens which retains at least one of a macrolide antibiotic or mycophenolic acid is also disclosed. This system provides a replacement lens ready for surgical implantation in a patient undergoing cataract surgery, with the lens containing a concentration of a macrolide antibiotic and/or mycophenolic acid. When the lens is implanted within the lens capsule of a patient's eye, the antibiotic or mycophenolic acid is then released to provide therapeutic effects to the capsule (e.g., anti-cell proliferative effects, anti-inflammatory effects, etc).
- In another embodiment, an ocular solution containing a supratherapeutic concentration of a macrolide antibiotic and/or mycophenolic acid is administered topically. The topically administered compounds accumulate within an ocular structure, such as the choroid, retina, or uvea, to a concentration effective to treat ocular pathologies affecting those structures. Such pathologies include diabetic retinopathy, retinitis pigmentosa, age related macular degeneration, scleritis, uveitis, vasculitis, retinoblastoma, choroidal melanoma, pre-malignant and malignant melanoma of the conjunctiva.
- In another embodiment, a supratherapeutic concentration of a macrolide antibiotic and/or mycophenolic acid is administered on a contact lens or intraocular device with the agent(s) in an extended release formulation. The agent(s) is formulated to release a maximum intraocular concentration up to about 40 μg/ml.
- These and other advantages of the invention will be apparent in light of the following figures and detailed description.
- An ocular solution containing one or more macrolide antibiotics and/or mycophenolic acid is disclosed. The ocular solution may be any physiologically compatible ocular solution. It may used externally (e.g. topical administration such as on the surface of the conjunctiva) or internally (e.g. invasive administration.)
- Ocular solutions are frequently administered to a patient following ocular surgery; macrolide antibiotics in these solutions desirably provide anti-inflammatory effects which aid in post-surgical recovery. In addition, macrolide antibiotics provide these anti-inflammatory effects without an increase in intraocular pressure that often accompanies administration of steroids to post-surgical patients to control inflammation.
- Macrolide antibiotics also reduce cell proliferation and cell migration. This may promote the healing process, and may also provide an anti-angiogenesis effect to retard the proliferation and/or growth of new vessels. As one example, controlling the growth of new blood vessels is a way to control proliferation of tumor cells; macrolide antibiotics in an ocular solution may be helpful in controlling ocular neoplasms or tumors. As another example, the solutions may be used in patients having diseases characterized by abnormal angiogenesis, such as certain types of cancers, diabetic retinopathy, and sickle cell retinopathy, in which an anti-angiogenesis effect is desirable. Macrolide antibiotics also provide antimicrobial and antifungal properties to ocular solutions.
- Macrolide antibiotics and/or mycophenolic acid may be used to enhance therapy in ocular diseases. Such enhancement is generally defined as treatment of these diseases. Treatment is not limited to total elimination of disease, but is broadly defined to include any enhancement or improvement toward the result of diminishing or alleviating the disease symptoms, onset, course, duration, severity, etc. The inventive use of macrolide antibiotics and/or mycophenolic acid may be combined with other agents, such as chemotherapeutic agents for treatment of ocular malignancies, and cyclooxygenase inhibitors for reducing inflammation. Both acute and chronic ocular diseases are treated by the inventive method and composition, and include retinitis pigmentosa, diabetic retinopathy, age related macular degeneration, scleritis, uveitis, and vasculitis. Ocular cancers such as retinoblastoma, choroidal melanoma, pre-malignant and malignant conjunctival melanoma are also treated by the invention.
- It will be appreciated that the inventive composition need not be in the physical form of a true solution, but instead may be a suspension, an emulsion, a gel, etc. It may also encompass the macrolide antibiotic and/or mycophenolic acid in the form of polymeric compositions, microspheres, microvesicles, microcapsules, and/or liposomes. In addition, ocular solutions for topical application may take the form of any of the above, as well as an ointment, a cream, a lotion, etc. Thus, the term solution is used for convenience but encompasses other physical states. It will also be appreciated that the macrolide antibiotics may be included in the formulation for preparing an ocular solution, or may be added in dry form or in concentrated form to an already prepared ocular solution.
- The ocular solution may be one that is used as an ocular irrigating solution and/or as a volume replacement solution during ocular surgery. It is thus a substitute for an ocular fluid, such as the vitreous, and/or a substitute for a commercially available irrigating solution that may be used during ocular surgery. It may also be one that is used topically, and thus encompasses eye drops, eye wash solutions, and contact lens solutions. It may be used in over the counter (OTC) ocular solutions for topical application, for example, in ocular solutions such as artificial tears or lubricants. One commercially available ophthalmic lubricant is Viva-Drops®, available from Vision Pharmaceuticals, Inc. (Mitchell S.D.). The invention includes but is not limited to this particular embodiment.
- In one embodiment, an ocular solution contains at least one macrolide antibiotic and/or mycophenolic acid and is used for intraocular administration. Intraocular administration indicates an invasive route of administration, compared to a topical route of administration. In this embodiment, the ocular solution containing the macrolide antibiotic(s) may be an irrigating solution, a volume replacement solution, and/or a wash solution.
- In another embodiment, an ocular solution containing a macrolide antibiotic and/or mycophenolic acid is administered topically, for example, on the conjunctiva or the mucosal surface of the lid, to treat diseases in other areas of the eye, such as the choroid, retina, and uvea. Administration of such compounds was previously restricted to systemic or invasive routes, because it was thought that the higher concentrations of these compounds in internal ocular structures required for efficacy could not be achieved by topical administration. However, an efficacious therapeutic concentration of a topically-administered macrolide antibiotic and/or mycophenolic acid in an ocular structure may be achieved by topically administering a supratherapeutic concentration for a duration such that a therapeutic concentration is attained in the diseased structure.
- While not bound by any theory, one reason this therapeutic concentration may be achieved with topical administration is that the structural affinity of the antibiotic and/or mycophenolic acid for lipids results in their accumulation in lipophilic regions of the choroid, retina, etc. Unexpectedly, such topically administered compositions can thus be used to treat pathologies that affect these structures without invasive methods, such as intraocular injection or systemic administration. Examples of pathologies include, but are not limited to, retinopathy including diabetic retinopathy, retinitis pigmentosa, age related macular degeneration, scleritis, uveitis, vasculitis, and oncological diseases affecting the eye such as retinoblastoma, choroidal melanoma, pre-malignant and malignant conjunctival melanoma. Retinoblastoma is a malignant tumor of the retina, typically affecting children under the age of six. Choroidal melanoma is a malignant tumor of the pigmented cells of the choroid. Melanoma of the conjunctiva may be classified as primary acquired melanosis (PAM) with or without atypia, or conjunctival melanoma. For cancers of the eye, treatment with a macrolide antibiotic/mycophenolic acid may provide an anti-angiogenic effect and thereby desirably diminish the blood supply to the tumor. Such treatment may augment or enhance the effects of specific radiation treatments and/or chemotherapeutic agents. For example, the macrolide antibiotic and/or mycophenolic acid may be added in polymer form, providing extended release, to carboplatin, cisplatin, methotrexate, etc., in topical chemotherapy eye drops. Diseases such as diabetic retinopathy, retinitis pigmentosa, and age related macular degeneration are typically chronic so that treatment is prolonged, while diseases such as scleritis, uveitis and vasculitis may be acute with treatment occurring for a shorter duration, that is, over the course of the disease. The invention encompasses both types of treatment, as will subsequently be described.
- The topically administered composition must cross ocular structures such as the conjunctiva and sclera to reach structures such as the choroid, retina, and uvea. In transit of the composition, a natural gradient of the active agent(s) may form within the eye. A structure such as the sclera may act as a depot or repository for the active agent(s), providing extended release. Thus, topical administration may provide results similar to a slow release formulation, as will be described. Such formulations desirably decrease the frequency of administration or dosing. For example, patients being treated with the inventive method already have decreased visual acuity, and topical ocular administration of drugs may be difficult and/or uncomfortable for them. Reducing the frequency of administration enhances compliance, while providing a therapeutic dosage of the composition.
- In one embodiment, a concentration of macrolide antibiotic and/or mycophenolic acid in a pharmaceutically acceptable topically administered solution may range from about 0.5%w/v to about 10%w/v. In another embodiment, a concentration of macrolide antibiotic and/or mycophenolic acid in a pharmaceutically acceptable topically administered solution may range from about 3%w/v to about 5%w/v. In another embodiment, a concentration of macrolide antibiotic and/or mycophenolic acid in a pharmaceutically acceptable topically administered solution may range from about 1%w/v to about 3%w/v. In another embodiment, a concentration of macrolide antibiotic and/or mycophenolic acid in a pharmaceutically acceptable topically administered solution may range from about 3%w/v to about 10%w/v. In another embodiment, a concentration of macrolide antibiotic and/or mycophenolic acid may range from about 0.1% to about 10% in a topical ocular formulation for treating diabetic retinopathy, age related macular degeneration, or retinitis pigmentosa. In another embodiment, concentrations of macrolide antibiotic and/or mycophenolic acid up to about 2%, up to about 5%, up to about 10%, or exceeding 10% are formulated for topical administration when the compound(s) is bound to a matrix or polymer which slowly releases the compound(s) over time while not exceeding an intraocular concentration of 40 μg/ml, as is subsequently described. In any of the above embodiments, the patient is typically instructed to periodically administer the solution, from once per day up to several times per day, over the course of the disease. In one embodiment, the composition may be administered daily at bedtime. It will be appreciated that some patients with a chronic disease will require continued treatment over many years.
- The inventive composition may be used in physiologic ophthalmic irrigating solutions. One example is Balanced Salt Solution (BSS®, available from Alcon Laboratories, Randburg, South Africa), containing per ml 0.64% sodium chloride, 0.075% potassium chloride, 0.048% calcium chloride, 0.03% magnesium chloride, 0.39% sodium acetate, and 0.17% sodium citrate dihydrate, as well as sodium hydroxide and/or hydrochloric acid to adjust pH, and water for injection. Another example is Ocular Irrigation Solution® (Allergan, Irvine Calif.). Another example is lactated Ringer's solution. Another example is a normal saline solution. Another example is normal saline adjusted to pH 7.4 with sodium bicarbonate.
- The inventive composition may also be used in ophthalmic volume replacement solutions. For example, it may be introduced into the posterior chamber of the eye to replace the vitreous that is removed during the repair of retinal disorders (vitrectomy).
- The inventive composition may also be introduced into the lens capsule during cataract surgery. A cloudy and discolored lens, referred to as a cataract, causes decreased vision and treatment requires that the lens be surgically removed. Cataract surgery usually involves phacoemulsification of the diseased lens inside the capsule, aspiration of the emulsified material, irrigation, and insertion of a replacement intraocular lens (IOL) within the capsule.
- Following cataract surgery, there is frequently opacification of the posterior capsule which also diminishes visual acuity. Surgical techniques to minimize posterior capsule opacification have variable success, and patients undergoing cataract surgery may require an additional procedure to attend to the capsular opacification that subsequently occurs.
- A complication for IOL implantation is post-operative opacification. This occurs as a result of lens epithelial cells (LEC) which migrate around the posterior capsule, and may be due to lack of maximum contact between the IOL optic and the posterior capsule. In children treated for pediatric cataracts, leaving the posterior capsule intact after IOL implantation predisposes them to secondary cataract formation and severe visual axis opacification (VAO). This usually requires surgery to prevent VAO and an anterior vitrectomy to maintain a clear visual axis during pediatric IOL surgery. Thus, reduction in the extent of cell migration and/or cell proliferation following cataract surgery is desirable.
- In this embodiment of the invention, an irrigating or volume replacement solution containing at least one macrolide antibiotic and/or mycophenolic acid is administered to the capsule with or before inserting the replacement lens. Without being bound by any theory, the macrolide antibiotic and/or mycophenolic acid may reduce posterior capsular opacification and visual axis opacification by its inhibitory effect on ocular cell proliferation and cell migration.
- The macrolide antibiotic and/or mycophenolic acid can also be provided on a device, such as a contact lens applied to the exterior surface of an eye, or a lens that will be implanted within a patient's eye. Implantable lenses include any IOL used to replace a patient's diseased lens following cataract surgery, including but not limited to those manufactured by Bausch and Lomb (Rochester N.Y.), Alcon (Fort Worth Tex.), Allergan (Irvine Calif.), and Advanced Medical Optics (Santa Ana Calif.). The system provides a therapeutic replacement lens ready for surgical implantation in a patient. When the lens is implanted within the lens capsule, the antibiotic and/or mycophenolic acid provides therapeutic effects (e.g., anti-cell proliferative effects, anti-inflammatory effects, etc) to the eye.
- A concentration of the macrolide antibiotic and/or mycophenolic acid within the capsule is provided to achieve the previously described therapeutic effect. In one embodiment, the concentration ranges from about 20 μg/ml (about 0.002%w/v) to about 2000 μg/ml (about 0.2%w/v). In another embodiment, the concentration ranges from about 200 μg/ml (about 0.02%w/v) to about 2000 μg/ml (about 0.2%w/v). In another embodiment, the concentration ranges from about 20 μg/ml (about 0.002%w/v) to about 200 μg/ml (about 0.02%w/v).
- In another embodiment, the IOL or device contains a concentration of the macrolide antibiotic and/or mycophenolic acid up to about 2%w/v formulated so that the concentration in the eye at any time does not exceed about 40 μg/ml. For example, the intraocular concentration of the active agent(s) at any time may be in the range of about 10 μg/ml to about 30 μg/ml. Such formulation methods are known to one skilled in the art and include, but are not limited to, extended release formulations subsequently described.
- The contact lens or IOL may be made of hydrophobic or hydrophilic material. The type of material determines whether the lens cannot fold, is rigid and requires a large incision to insert, or is flexible to allow the lens to be rolled, compressed, or folded for insertion through a smaller incision. The most common materials used in lenses are various chemical modifications of silicon, hydrophobic acrylates, hydrophobic acrylates, and hydrogels which contain water to impart gel-like characteristic to the material. Each of these can be formulated or treated to contain a solution containing a macrolide antibiotic and/or mycophenolic acid.
- In one embodiment, the contact lens or implantable IOL is packaged in an ophthalmically acceptable medium which contains the macrolide antibiotic and/or mycophenolic acid. For example, a porous hydrogel lens (e.g., Hydroview®, Bausch & Lomb Surgical, Rochester N.Y.) retains the macrolide antibiotic and/or mycophenolic acid within the pores. Upon application of the contact lens or insertion/implantation of the lens into the lens capsule, the macrolide antibiotic and/or mycophenolic acid is released. An ocular device containing agent(s) in a slow-release system provides extended therapy, for example, over a post-surgical recovery period as the actives are slowly released through the porous elements. It may also be the administration method of choice in some patients, such as patients who are elderly, who cannot reliably self-administer topical ocular medications, who must receive chronic therapy, etc.
- In another embodiment, a contact lens or implantable lens is coated to provide the macrolide antibiotic and/or mycophenolic acid. This embodiment may be used with a non-hydrogel hydrophilic lens, a hydrophobic lens, a lens made from an acrylic material (e.g., AcrySof®; Alcon, Fort Worth Tex.; Sensar®; Advanced Medical Optics, Santa Ana Calif.), a silicone lens (e.g., CeeOn®, Pharmacia & Upjohn Company, Pickering Ohio), etc. Coating and/or incorporation procedures that may be used are known to one skilled in the art; for example, as disclosed in U.S. Pat. Nos. 6,238,799; 6,179,817; 6,306,422; and 6,258,856, each of which is incorporated by reference herein in its entirety. The macrolide antibiotic and/or mycophenolic acid may be added to the storage solution during packaging of the lens, or may be incorporated into the manufacture of the lens. For example, the macrolide antibiotic and/or mycophenolic acid may be incorporated into either or both the hydration fluid in the formation of a hydrophilic or hydrogel lens, or in the storage solution. In another example, the macrolide antibiotic and/or mycophenolic acid may be in an acceptable encapsulated form in a hydrogel IOL for extended long term release.
- The inventive composition may also be used as an ocular wash solution, for example, to clear the surgical field during intraocular surgery.
- In each of the above embodiments, any macrolide antibiotic alone or in combination may be used. Embodiments of the invention include various ocular-compatible concentrations of the macrolide antibiotic(s) and/or mycophenolic acid sufficient to provide an anti-inflammatory, anti-proliferative, anti-cell migration, anti-fungal, etc. effect. Concentrations may depend upon the use for the composition, as is known to one skilled in the art. Thus, in these embodiments, the invention is not limited to a specific concentration of macrolide antibiotic and/or mycophenolic acid. In general, the macrolide antibiotic and/or mycophenolic acid is present in the ocular solution at concentrations ranging from about 1 ng/ml (about 0.0000001%w/v) to about 200 μg/ml (about 0.02%w/v). In one embodiment, the macrolide antibiotic and/or mycophenolic acid is present in the ocular solution at a concentration of about 1 μg/ml (about 0.0001%w/v) For use to reduce capsular opacification following cataract surgery, concentrations ranging from about 1 μg/ml (about 0.0001%w/v) to about 200 μg/ml (about 0.02%w/v), or from about 20 μg/ml (about 0.002%w/v) to about 200 μg/ml (about 0.02%w/v), may be used. The properties of the macrolide- and/or mycophenolic acid-containing ocular solution are compatible with ocular tissues.
- The macrolide antibiotic and/or mycophenolic acid may be formulated with a viscoelastic substance such as hyaluranic acid, or may be contained in microspheres, macrospheres, microvesicles, macrovesicles, microcapsules, macrocapsules, liposomes, etc., as described in co-pending U.S. patent application Ser. No. 10/631,143 which is expressly incorporated by reference herein in its entirety. This embodiment may be used with solutions administered to prevent capsular opacification following cataract surgery, as previously described.
- Liposomes may be prepared from dipalmitoyl phosphatidylcholine (DPPC), for example, from egg phosphatidylcholine (PC), a lipid with a low heat of transition. Liposomes are made using standard procedures as known to one skilled in the art. The macrolide antibiotic(s), in amounts ranging from nanogram to microgram quantities, or higher, is added to a solution of egg PC, and the lipophilic drug binds to the liposome.
- A time-release drug delivery system may be administered intraocularly to result in sustained release of the macrolide antibiotic(s) over a period of time. The formulation may be in the form of a vehicle, such as a micro- or macro-capsule or matrix of biocompatible polymers such as polycaprolactone, polyglycolic acid, polylactic acid, polyanhydrides, polylactide-co-glycolides, polyamino acids, polyethylene oxide, acrylic terminated polyethylene oxide, polyamides, polyethylenes, polyacrylonitriles, polyphosphazenes, poly(ortho esters), sucrose acetate isobutyrate (SAIB), and other polymers such as those disclosed in U.S. Pat. Nos. 6,667,371; 6,613,355; 6,596,296; 6,413,536; 5,968,543; 4,079,038; 4,093,709; 4,131,648; 4,138,344; 4,180,646; 4,304,767; 4,946,931, each of which is expressly incorporated by reference herein in its entirety, or lipids that may be formulated as microspheres or liposomes. A microscopic or macroscopic formulation may be administered through a needle, or may be implanted by suturing within the eye, for example, within the lens capsule. As an illustrative example, sirolimus may be mixed with polyvinyl alcohol (PVA), the mixture then dried and coated with ethylene vinyl acetate, then cooled again with PVA. In a formulation for intraocular administration, the liposome capsule degrades due to cellular digestion providing a slow release drug delivery system, allowing the patient a constant exposure to the drug over time.
- A time-release microscopic or macroscopic formulation may also be topically administered. The sustained-release antibiotic(s) and/or mycophenolic acid accumulates at concentrations in ocular structures such as the choroid or retina sufficient to effect treatment and diseases affecting these structures.
- Delayed or extended release properties may be provided through various formulations of the vehicle (coated or uncoated microsphere, coated or uncoated capsule, lipid or polymer components, unilamellar or multilamellar structure, and combinations of the above, etc.). Other variables may include the patient's pharmacokinetic-pharmacodynamic parameters (e.g., body mass, gender, plasma clearance rate, hepatic function, etc.). The formulation and loading of microspheres, microcapsules, liposomes, etc. and their ocular implantation are standard techniques known by one skilled in the art, for example, the use a ganciclovir sustained-release implant to treat cytomegalovirus retinitis, disclosed in Vitreoretinal Surgical Techniques, Peyman et al., Eds. (Martin Dunitz, London 2001, chapter 45); Handbook of Pharmaceutical Controlled Release Technology, Wise, Ed. (Marcel Dekker, New York 2000), the relevant sections of which are incorporated by reference herein in their entirety.
- Examples of macrolide antibiotics that may be used for intraocular administration include, but are not limited to, tacrolimus, Cyclosporin A, sirolimus, ascomycin, and everolimus. Tacrolimus (Prograf®, Fujisawa Healthcare, Deerfield, Ill.; FK-506), a macrolide immunosuppressant produced by Streptomyces tsukubaensis, is a tricyclo hydrophobic compound that is practically insoluble in water, but is freely soluble in ethanol and is very soluble in methanol and chloroform. It is available under prescription as either capsules for oral administration or as a sterile solution for intravenous administration. The solution contains the equivalent of 5 mg anhydrous tacrolimus in 1 ml of polyoxyl 60 hydrogenated castor oil (HCO-60), 200 mg, and dehydrated alcohol (USP, 80.0%w/v), and must be diluted with a solution of 0.9% NaCl or 5% dextrose before use.
- Tacrolimus has been used for topical administration to treat a variety of dermatoses. Topical administration of tacrolimus at doses ranging from 0.03%-0.3% resulted in significant clinical improvement in atopic dermatitis after 2-3 weeks treatment, and tacrolimus treatment of other dermatologic diseases shows promise. Tacrolimus, like cyclosporine, blocks the signal transduction pathway needed to induce interleukin-2 gene expression and thereby activate T lymphocytes. In addition to suppressing T cell activation, tacrolimus inhibits anti-IgE-triggered histamine release and inhibits prostaglandin D2 synthesis in human skin mast cells. While oral administration produces limiting adverse effects (systemic immunosuppression, infection, neural toxicity, nephrotoxicity, and hypertension), topical administration for treatment of dermatoses at concentrations up to 0.3% showed no significant difference in effects between treated and control groups. In addition, tacrolimus is well tolerated locally and only occasionally causes mild irritation.
- The use of tacrolimus as a specific medicament for treatment of ocular disease has been disclosed in U.S. Pat. No. 6,489,335 and co-pending U.S. patent application Ser. No. 10/247,220, each of which is expressly incorporated by reference herein in its entirety. For example, tacrolimus may be contained in an aqueous-based cream excipient for topical application, or it may be injected intraocularly, or it may be administered surgically as an ocular implant.
- None of these publications disclose the topical ocular administration of supratherapeutic concentrations of a macrolide antibiotic and/or mycophenolic acid, either alone or with other agents such as chemotherapeutic agents and/or inhibitors of cyclooxygenase, at the disclosed doses and formulations for treating ocular pathologies such as diabetic retinopathy, retinitis pigmentosa, age related macular degeneration, uveitis, vasculitis, retinoblastoma, choroidal melanoma, pre-malignant and malignant melanoma of the conjunctiva, as in the inventive method.
- Cyclosporin A (cyclosporine, topical formulation Arrestase®, Allergan Inc.) is a cyclic peptide produced by Trichoderma polysporum. It is available commercially, for example, from Sigma-Aldrich (St. Louis Mo.). It is an immunosuppressant and acts in a particular subset of T lymphocytes, the helper T cells. Cyclosporin A exerts an immunosuppressant effect by inhibiting production of the cytokine interleukin 2. Each of Cyclosporin A and tacrolimus, another immunosuppressant, produce significant renal and hepatic toxicity when each is administered systemically; because of this toxicity, they are not administered together.
- Cyclosporin A has been administered to treat ocular conditions such as glaucoma, corticosteroid-induced ocular hypertension, allograft rejection, infections, and ocular surface disease. Its use has been reported for the treatment of uveitis (inflammation of the uvea) by topical, intravitreal or systemic administration with doses of 0.05%, 0.1%, and 0.5%. Cyclosporin A has good penetration into the cornea but not into the anterior chamber, and does not increase intraocular pressure or cause cataracts. Its known toxicity had previously limited its use for other ocular diseases.
- The use of Cyclosporin A as a specific medicament for treatment of ocular disease with reduced toxicity has been described in co-pending U.S. patent application Ser. No. 10/289,772, which is expressly incorporated by reference herein in its entirety.
- Sirolimus, also known as rapamycin, RAPA, and Rapamun®, is a triene macrolide antibiotic derived from Streptomyces hydroscopicus and originally developed as an antifungal agent. Subsequently, it has shown anti-inflammatory, anti-tumor, and immunosuppressive properties. Ascomycin, also known as pimecrolimus, Immunomycin, and FR-900520, is an ethyl analog of tacrolimus and has strong immunosuppressant properties. It inhibits Th1 and Th2 cytokines, and preferentially inhibits activation of mast cells, and is used to treat contact dermatitis and other dermatological conditions. Sirolimus and ascomycin are commercially available, e.g., A.G. Scientific, Inc. (San Diego, Calif.).
- Regarding its immunosuppressive potential, sirolimus has some synergetic effect with Cyclosporin A. It has been reported that sirolimus has a different mode of action compared to Cyclosporin A and tacrolimus. All three agents are immunosuppresants which affect the action of immune cell modulators (cytokines), but do not affect the immune cells themselves. However, while all three agents affect immune cell modulators, they do so differently: Cyclosporin A and tacrolimus prevent synthesis of cytokine messengers, specifically interleukin-2, while sirolimus acts on cytokine that has already been synthesized, preventing it from reaching immune cells.
- Sirolimus inhibits inflammation by acting on both T-lymphocytes and dendritic cells. The latter are the first cells to recognize antigens. Sirolimus blocks the growth of dendritic cells and a number of other cells, such as tumors and endothelial cells, which are activated by the tumor cell releasing vascular endothelial growth factor (VEGF). VEGF is a central regulator of angiogenesis (formation of new blood vessels from pre-existing vessels) and vasculogenesis (development of embryonic vasculature through an influence on endothelial cell differentiation and organization). Diseases that are characterized by abnormal angiogenesis and vasculogenesis, such as some cancers and some ocular diseases, may show abnormal production of VEGF. Thus, control of VEGF function may be one means to control or treat these diseases. Sirolimus has also been used in the prevention of smooth muscle hyperplasia after coronary stent surgery. The use of sirolimus and ascomycin as specific medicaments for treatment of ocular disease has been disclosed in co-pending U.S. Patent application Serial No. 10/631,143, which is expressly incorporated by reference herein in its entirety.
- Everolimus, also known as RAD-001, SCZ RAD, Certican™ (Novartis, Basel Switzerland), is an analog of sirolimus but is a new and distinct chemical entity. It is an oral immunosuppressant that inhibits growth factor-induced cell proliferation and thus reduces acute organ rejection and vasculopathy, the proliferation of smooth muscle cells in the innermost wall of grafts that restricts blood supply.
- Mycophenolic acid (MPA) is the active compound formed following the administration of mycophenolate mofetil (MMF). The prodrug is the morpholinoethyl ester of mycophenolic acid. Mycophenolic acid is an antileukemic and immunosuppressant agent used in patients undergoing chemotherapy for cancer and in transplant recipients.
- The topical ocular administration of these agents, either alone, in combination, or with chemotherapeutic agents or cyclooxygenase inhibitors, at the disclosed concentrations and formulations to treat ocular pathologies such as diabetic retinopathy, retinitis pigmentosa, age related macular degeneration, uveitis, vasculitis, retinoblastoma, choroidal melanoma, pre-malignant and malignant conjunctival melanoma has not been reported.
- The addition of these agents, either alone or in combination, to invasively administered ocular solutions according to the invention provides beneficial anti-inflammatory, anti-proliferative, anti-cell migration, anti-angiogenic, antimicrobial, and antifungal properties.
- It will be appreciated that the invention encompasses the use of macrolide antibiotics and/or mycophenolic acid, in addition to those previously described, in an ocular solution. These include, for example, the known antibiotics erythromycin and its derivatives such as azithromycin and clarithromycin, lincomycin, dirithromycin, josamycin, spiramycin, diacetylmidecamycin, troleandomycin, tylosin, and roxithromycin. The invention also includes new macrolide antibiotic scaffolds and derivatives in development, including but not limited to the ketolides ABT-773 and telithromycin as described by Schonfeld and Kirst (Eds.) in Macrolide Antibiotics, Birkhauser, Basel Switzerland (2002); macrolides derived from leucomycins, as described in U.S. Pat. Nos. 6,436,906; 6,440,942; and 6,462,026 assigned to Enanta Pharmaceuticals (Watertown Mass.); and lincosamides.
- In addition to the above described uses, the invention comprises ocular solutions for topical (non-invasive) ocular administration with everolimus, erythromycin, azithromycin, clarithromycin, lincomycin, dirithromycin, josamycin, spiramycin, diacetyl-midecamycin, tylosin, roxithromycin, and mycophenolic acid, as well as the previously described new macrolide antibiotic scaffolds and derivatives in development, including but not limited to the ketolides ABT-773 and telithromycin, macrolides derived from leucomycins, and lincosamides.
- The macrolide antibiotics are included with ocular solutions for any use. They may be included with topical ocular solutions containing chemotherapeutic agents for treating ocular malignancies or pre-malignant conditions. They may be included with topical ocular solutions containing inhibitors of cyclooxygenase for reducing ocular inflammation. In one embodiment, age related macular degeneration is treated by administering a topical ocular formulation containing at least one macrolide antibiotic and/or mycophenolic acid and at least on cyclooxygenase inhibitor. The cyclooxygenase inhibitor(s) may be present in a concentration of 0.5% to 20% of the composition. Inhibitors of cyclooxygenase (COX inhibitors) are well known (e.g., Viiox®, Celebrex®) and include, but are not limited to, ibuprofen, indomethacin, piroxicam, and tranylcypromine HCl. The macrolide antibiotic may be added together or separately as individual components in the preparation of an ocular solution. Alternatively, a solution of the macrolide antibiotic may be prepared and then added to the ocular solution. The solutions may be commercial irrigating solutions that contain other known components, such as various anions and cations, buffers to regulate pH, adenosine, calcium, glucose, bicarbonate, dextrose, dextran 40 (a low molecular weight colloidal osmotic agent), gentamicin, dexamethasone, selenium, zinc, and gluconide. The macrolide antibiotic may be added to commercial ocular lubricating solutions, such as artificial tears. The macrolide antibiotic may be included with commercial ocular wash solutions. The macrolide antibiotic may be included with contact lens wash, rinse, and wetting solutions. Any solution for ocular administration, either administration to the exterior surface of the eye or to one of the interior chambers of the eye, may contain the macrolide antibiotic.
- The invention is also not limited to human use, and encompasses the use of ocular solutions containing at least one macrolide antibiotic for veterinary use. For example, lincosamides have been used in animals; an ocular solution containing a lincosamide may be used as a veterinary irrigation solution, volume replacement solution, topical wash or lubricant solution, etc.
- The invention provides general purpose ocular solutions in the form of eye drops, eye washes, eye irrigating solutions, volume replacement solutions, contact lens solutions, etc. that contain one or more of the above macrolide antibiotics. In various embodiments, the ocular solution may be in single or multi-dose containers (e.g., 10 ml, 20 ml, 30 ml, 500 ml).
- Other variations or embodiments of the invention will also be apparent to one of ordinary skill in the art from the above figures and descriptions. Thus, the forgoing embodiments are not to be construed as limiting the scope of this invention.
Claims (34)
1. A non-invasive method to treat a diseased eye in a patient: comprising topically administering to the patient a composition comprising a concentration ranging between 0.5%w/v to about 10%w/v of a macrolide antibiotic and/or mycophenolic acid in a pharmaceutically acceptable topical formulation for a duration to achieve a concentration of the macrolide antibiotic and/or mycophenolic in a diseased ocular structure sufficient to treat the diseased eye.
2. The method of claim 1 wherein the diseased ocular structure is at least one of the choroid, retina, or uvea.
3. The method of claim 1 wherein the macrolide antibiotic is selected from at least one of tacrolimus, Cyclosporin A, sirolimus, ascomycin, and everolimus.
4. The method of claim 1 wherein the macrolide antibiotic is selected from at least one of erythromycin, azithromycin, clarithromycin, lincomycin, dirithromycin, josamycin, spiramycin, diacetyl-midecamycin, tylosin, troleandomycin, roxithromycin, ABT-773, telithromycin, macrolides derived from leucomycins, and lincosamides.
5. The method of claim 1 wherein the composition is an extended-release formulation.
6. The method of claim 5 wherein the composition is provided on a contact lens or intraocular lens.
7. The method of claim 1 wherein the composition is formulated as at least one of a polymer, a microcapsule, a microsphere, a microvesicle, and a liposome.
8. The method of claim 1 for treating at least one of retinopathy, retinitis pigmentosa, age related macular degeneration, scleritis, uveitis, vasculitis, retinoblastoma, choroidal melanoma, and pre-malignant and malignant melanoma of the conjunctiva.
9. The method of claim 1 for administration to at least one of an ocular mucosal surface or the conjunctiva.
10. The method of claim 1 wherein the concentration of the macrolide antibiotic and/or mycophenolic acid is from at least one of about 0.5%w/v to about 3%w/v, about 3%w/v to about 5%w/v, about 5%w/v to about 10%ww/v, or about 3%w/v to about 10%w/v,
11. The method of claim 1 for treating age related macular degeneration wherein the composition further comprises a cyclooxygenase inhibitor.
12. A non-invasive method to treat a diseased eye in a patient comprising topically administering to the eye a composition consisting essentially of tacrolimus at a concentration from 0.5%w/v to about 10%w/v in a pharmaceutically acceptable formulation for a duration to achieve a concentration in an internal ocular structure sufficient to treat the structure.
13. The method of claim 12 for treating at least one of retinopathy, retinitis pigmentosa, age related macular degeneration, uveitis, vasculitis, retinoblastoma, choroidal melanoma, and pre-malignant and malignant melanoma of the conjunctiva.
14. A non-invasive method to treat a diseased eye in a patient comprising topically administering to the eye a composition consisting essentially of Cyclosporin A at a concentration from 0.5%w/v to about 10%w/v in a pharmaceutically acceptable formulation for a duration to achieve a concentration in an internal ocular structure sufficient to treat the structure.
15. The method of claim 14 for treating at least one of retinopathy, retinitis pigmentosa, age related macular degeneration, uveitis, vasculitis, retinoblastoma, choroidal melanoma, pre-malignant and malignant melanoma of the conjunctiva.
16. A non-invasive method to treat a diseased eye in a patient comprising topically administering to the eye a composition consisting essentially of sirolimus at a concentration from 0.5%w/v to about 10%w/v in a pharmaceutically acceptable formulation for a duration to achieve a concentration in an internal ocular structure sufficient to treat the structure.
17. The method of claim 16 for treating at least one of retinopathy, retinitis pigmentosa, age related macular degeneration, uveitis, vasculitis, retinoblastoma, choroidal melanoma, pre-malignant and malignant melanoma of the conjunctiva.
18. A non-invasive method to treat a diseased eye in a patient comprising topically administering to the eye a composition consisting essentially of ascomycin at a concentration from 0.5%w/v to about 10%w/v in a pharmaceutically acceptable formulation for a duration sufficient to achieve a concentration in an internal ocular structure sufficient to treat the structure.
19. The method of claim 18 for treating at least one of retinopathy, retinitis pigmentosa, age related macular degeneration, uveitis, vasculitis, retinoblastoma, choroidal melanoma, and pre-malignant and malignant melanoma of the conjunctiva.
20. A non-invasive method to treat a diseased eye in a patient comprising topically administering to the eye a composition consisting essentially everolimus of at a concentration from 0.5%w/v to about 10%w/v in a pharmaceutically acceptable formulation for a duration to achieve a concentration in an internal ocular structure sufficient to treat the structure.
21. The method of claim 20 for treating at least one of retinopathy, retinitis pigmentosa, age related macular degeneration, uveitis, vasculitis, retinoblastoma, choroidal melanoma, and pre-malignant and malignant melanoma of the conjunctiva.
22. A topical ocular composition comprising at least one macrolide antibiotic and/or mycophenolic acid a concentration ranging from about 0.5%w/v to about 10%w/v and at least one of a polymer, a liposome, a microcapsule, and a microsphere in a pharmaceutically acceptable extended release topical ocular formulation.
23. The composition of claim 22 wherein the macrolide antibiotic is at least one of tacrolimus, cyclosporine, sirolimus, everolimus, ascomycin, erythromycin, azithromycin, clarithromycin, clindamycin, lincomycin, dirithromycin, josamycin, spiramycin, diacetyl-midecamycin, tylosin, roxithromycin, ABT-773, telithromycin, leucomycins, and lincosamide.
24. The composition of claim 22 provided with a contact lens or an intraocular lens.
25. The composition of claim 24 wherein the composition is on a lens surface.
26. The composition of claim 24 wherein the composition is contained in pores of a porous lens.
27. The composition of claim 22 further comprising at least one of a cyclooxygenase inhibitor or a chemotherapeutic agent.
28. An article comprising an ocular lens containing a concentration of at least one macrolide antibiotic and/or mycophenolic acid in a formulation to slowly release from the lens an intraocular concentration of the macrolide antibiotic and/or mycophenolic acid that does not exceed about 40 μg/ml.
29. The article of claim 28 wherein the intraocular concentration of macrolide antibiotic and/or mycophenolic acid ranges from about 10 μg/ml to about 30 μg/ml.
30. The article of claim 28 wherein the lens is a contact lens or an intraocular lens.
31. A non-invasive method to treat a diseased eye in a patient having diabetic retinopathy, age related macular degeneration, or retinitis pigmentosa, the method comprising topically administering to the patient a composition comprising a concentration ranging between 0.1%w/v to about 10%w/v of a macrolide antibiotic and/or mycophenolic acid in a pharmaceutically acceptable topical formulation for a duration to achieve a concentration of the macrolide antibiotic and/or mycophenolic in a diseased ocular structure sufficient to treat the diseased eye.
32. The method of claim 31 wherein the macrolide antibiotic and/or mycophenolic acid is formulated for extended release.
33. The method of claim 31 wherein the macrolide antibiotic and/or mycophenolic acid is provided with a contact lens or intraocular lens.
34. The method of claim 31 wherein the composition further comprises at least one cyclooxygenase inhibitor.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/451,100 US20060228394A1 (en) | 2003-09-19 | 2006-06-12 | Ocular solutions |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/667,161 US7087237B2 (en) | 2003-09-19 | 2003-09-19 | Ocular solutions |
US10/752,124 US7083803B2 (en) | 2003-09-19 | 2004-01-06 | Ocular solutions |
US11/451,100 US20060228394A1 (en) | 2003-09-19 | 2006-06-12 | Ocular solutions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/752,124 Continuation US7083803B2 (en) | 2003-09-19 | 2004-01-06 | Ocular solutions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060228394A1 true US20060228394A1 (en) | 2006-10-12 |
Family
ID=34313266
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/667,161 Expired - Fee Related US7087237B2 (en) | 2003-09-19 | 2003-09-19 | Ocular solutions |
US11/451,100 Abandoned US20060228394A1 (en) | 2003-09-19 | 2006-06-12 | Ocular solutions |
US11/451,052 Abandoned US20060228393A1 (en) | 2003-09-19 | 2006-06-12 | Ocular solutions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/667,161 Expired - Fee Related US7087237B2 (en) | 2003-09-19 | 2003-09-19 | Ocular solutions |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/451,052 Abandoned US20060228393A1 (en) | 2003-09-19 | 2006-06-12 | Ocular solutions |
Country Status (6)
Country | Link |
---|---|
US (3) | US7087237B2 (en) |
EP (1) | EP1670465A1 (en) |
JP (1) | JP2007505906A (en) |
AU (1) | AU2004275703A1 (en) |
CA (1) | CA2539472A1 (en) |
WO (1) | WO2005030205A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090156881A1 (en) * | 2007-10-15 | 2009-06-18 | Stokes John P | Convergent well irradiating plaque for choroidal melanoma |
US20100010082A1 (en) * | 2008-07-09 | 2010-01-14 | Aspreva International Ltd. | Formulations for treating eye disorders |
US20100022465A1 (en) * | 2008-07-10 | 2010-01-28 | Brubaker Kurt E | Method of treating blepharitis |
US20100092452A1 (en) * | 2008-05-07 | 2010-04-15 | The Regents Of The University Of California | Replenishment and Enrichment of Ocular Surface Lubrication |
US20100190734A1 (en) * | 2009-01-23 | 2010-07-29 | Romulus Kimbro Brazzell | Method of treating dry eye disease with azithromycin |
US20110059902A1 (en) * | 2008-05-07 | 2011-03-10 | The Regents Of The University Of California | Therapeutic Replenishment and Enrichment of Ocular Surface Lubrication |
US8106111B2 (en) | 2009-05-15 | 2012-01-31 | Eastman Chemical Company | Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions |
US8222271B2 (en) | 2006-03-23 | 2012-07-17 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
US8367097B2 (en) | 2005-02-09 | 2013-02-05 | Santen Pharmaceutical Co., Ltd. | Liquid formulations for treatment of diseases or conditions |
US8492400B2 (en) | 2006-02-09 | 2013-07-23 | Santen Pharmaceutical Co., Ltd. | Stable formulations, and methods of their preparation and use |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
WO2014150067A1 (en) * | 2013-03-15 | 2014-09-25 | Insite Vision Incorporated | Concentrated aqueous azalide formulations |
US10172789B2 (en) | 2013-01-24 | 2019-01-08 | Palvella Therapeutics Llc | Compositions for transdermal delivery of mTOR inhibitors |
WO2018220444A3 (en) * | 2017-05-30 | 2019-02-28 | Eximore Ltd. | Compositions and methods for treating dry eye syndrome delivering antibiotic macrolide |
US10722499B2 (en) | 2017-01-06 | 2020-07-28 | Palvella Therapeutics, Inc. | Anyhydrous compositions of mTOR inhibitors and methods of use |
US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7090750B2 (en) * | 2002-08-26 | 2006-08-15 | Micron Technology, Inc. | Plating |
US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
US20060177430A1 (en) * | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
US7083802B2 (en) | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
US7087237B2 (en) * | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
AU2005209201B2 (en) | 2004-01-20 | 2010-06-03 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
US20070014760A1 (en) * | 2005-07-18 | 2007-01-18 | Peyman Gholam A | Enhanced recovery following ocular surgery |
WO2007011880A2 (en) * | 2005-07-18 | 2007-01-25 | Minu, L.L.C. | Enhanced ocular neuroprotection/neurostimulation |
JP2007277213A (en) * | 2006-04-04 | 2007-10-25 | Kazuaki Sugata | Medicine for treating retinal disorder and use thereof |
US20070299420A1 (en) * | 2006-06-23 | 2007-12-27 | Minu, L.L.C. | Delivery of an agent using iontophoresis |
US20070299386A1 (en) * | 2006-06-23 | 2007-12-27 | Minu, L.L.C. | Delivery of an ocular agent using iontophoresis |
EP2412359A1 (en) | 2006-09-29 | 2012-02-01 | Infa S.A. | Packaging system for pharmaceutical compositions and kit for intravenous administration |
WO2008127746A1 (en) | 2007-01-10 | 2008-10-23 | Board Of Regents The University Of Texas System | Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery |
CA2683415C (en) | 2007-04-04 | 2020-12-08 | Sigmoid Pharma Limited | An oral pharmaceutical composition |
EP2586428B1 (en) | 2007-04-26 | 2023-11-08 | Sublimity Therapeutics Limited | Manufacture of multiple minicapsules |
BRPI0811538A2 (en) | 2007-05-04 | 2015-08-11 | Allergan Inc | Use of cyclosporins in the treatment of patients with intraocular lenses. |
MX2010003364A (en) | 2007-10-08 | 2010-07-06 | Lux Biosciences Inc | Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors. |
US20100158821A1 (en) * | 2008-12-22 | 2010-06-24 | Eastman Chemical Company | Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products |
JP2010260857A (en) * | 2009-04-10 | 2010-11-18 | Santen Pharmaceut Co Ltd | Therapeutic agent for chorioretinal disease comprising sirolimus derivative as active ingredient |
US9278070B2 (en) | 2009-05-18 | 2016-03-08 | Sigmoid Pharma Limited | Composition comprising oil drops |
AU2010259184B2 (en) * | 2009-06-09 | 2015-08-13 | Aurinia Pharmaceuticals Inc. | Topical drug delivery systems for ophthalmic use |
GB2485327A (en) | 2009-08-12 | 2012-05-09 | Sigmoid Pharma Ltd | Immunomodulatory compositions comprising a polymer matrix and an oil phase |
US20110116872A1 (en) * | 2009-11-13 | 2011-05-19 | Restoration Products, LLC | Composition and method for remediation of heavy metal contaminated substances |
WO2011080984A1 (en) * | 2009-12-29 | 2011-07-07 | Senju Pharmaceutical Co., Ltd. | Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction |
GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
ES2666857T3 (en) | 2011-07-18 | 2018-05-08 | Mor-Research Applications Ltd. | A device to adjust intraocular pressure |
GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
CA3050298A1 (en) * | 2012-08-24 | 2014-02-27 | Sun Pharma Global Fze | Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and polyalkoxylated alcohol for use in the treatment of ocular conditions |
GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
KR20170102223A (en) | 2014-11-07 | 2017-09-08 | 시그모이드 파마 리미티드 | Compositions comprising cyclosporin |
US10500091B2 (en) | 2014-11-10 | 2019-12-10 | Forsight Vision4, Inc. | Expandable drug delivery devices and methods of use |
EP3200840B1 (en) * | 2014-12-16 | 2021-11-17 | Alcon Inc. | Low-water content acrylate-acrylamide copolymers for ophthalmic devices |
US9789080B2 (en) | 2015-09-04 | 2017-10-17 | Insite Vision Incorporated | Ophthalmic formulations of mycophenolic acid |
JP7072517B2 (en) | 2016-02-29 | 2022-05-20 | サン ファーマ グローバル エフゼットイー | Topical cyclosporine-containing preparations and their use |
RU2618167C1 (en) * | 2016-03-16 | 2017-05-02 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Method for treatment of inflammatory eye diseases associated with autoimmune pathologies |
US11617680B2 (en) | 2016-04-05 | 2023-04-04 | Forsight Vision4, Inc. | Implantable ocular drug delivery devices |
CA2972296A1 (en) * | 2016-06-30 | 2017-12-30 | Durect Corporation | Depot formulations |
US9981041B2 (en) * | 2016-08-23 | 2018-05-29 | Ira Jason Salzman | Ophthalmic lubricating spray |
US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
US20200163984A1 (en) * | 2017-07-04 | 2020-05-28 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | Use of isovaleryl spiramycin i, ii and/or iii in manufacturing medicament for treating and/or preventing tumor, and medicament |
CN109381707B (en) * | 2017-08-03 | 2022-02-15 | 沈阳药科大学 | Azithromycin ion pair liposome eye drops and preparation method thereof |
US11766421B2 (en) | 2017-09-25 | 2023-09-26 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
JP2022516099A (en) * | 2018-12-27 | 2022-02-24 | サーフィス オフサルミクス,インコーポレイテッド | Ophthalmic pharmaceutical composition and treatment method for cancer surface diseases |
Citations (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4079038A (en) * | 1976-03-05 | 1978-03-14 | Alza Corporation | Poly(carbonates) |
US4093709A (en) * | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
US4131648A (en) * | 1975-01-28 | 1978-12-26 | Alza Corporation | Structured orthoester and orthocarbonate drug delivery devices |
US4180646A (en) * | 1975-01-28 | 1979-12-25 | Alza Corporation | Novel orthoester polymers and orthocarbonate polymers |
US4304767A (en) * | 1980-05-15 | 1981-12-08 | Sri International | Polymers of di- (and higher functionality) ketene acetals and polyols |
US4946931A (en) * | 1989-06-14 | 1990-08-07 | Pharmaceutical Delivery Systems, Inc. | Polymers containing carboxy-ortho ester and ortho ester linkages |
US5294604A (en) * | 1989-12-20 | 1994-03-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating ocular diseases by periocular administration of cyclosporine A or G |
US5387589A (en) * | 1991-07-25 | 1995-02-07 | University Of Louisville Research Foundation, Inc. | Method of treating ocular inflammation |
US5387335A (en) * | 1990-11-21 | 1995-02-07 | Iwai; Isamu | Filter circulating type sewage disposal apparatus |
US5411952A (en) * | 1987-09-03 | 1995-05-02 | University Of Georgia Research Foundation, Inc. | Ocular cyclosporine composition |
US5457182A (en) * | 1994-02-15 | 1995-10-10 | Merck & Co., Inc. | FK-506 cytosolic binding protein, FKBP12.6 |
US5770607A (en) * | 1989-07-05 | 1998-06-23 | Fujisawa Pharmaceutical Co., Ltd. | Aqueous liquid composition for external use |
US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
US5952371A (en) * | 1996-10-16 | 1999-09-14 | Merck & Co., Inc. | Triterpene derivatives with immunosuppressant activity |
US5968543A (en) * | 1996-01-05 | 1999-10-19 | Advanced Polymer Systems, Inc. | Polymers with controlled physical state and bioerodibility |
US6004565A (en) * | 1997-09-02 | 1999-12-21 | Yoshitomi Pharmaceutical Industries, Ltd. | Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties |
US6179817B1 (en) * | 1995-02-22 | 2001-01-30 | Boston Scientific Corporation | Hybrid coating for medical devices |
US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
US6238799B1 (en) * | 1996-02-09 | 2001-05-29 | Surface Solutions Laboratories, Inc. | Articles prepared from water-based hydrophilic coating compositions |
US6258856B1 (en) * | 1996-12-19 | 2001-07-10 | The University Of Sydney | Method for preventing or controlling cataract |
US6306422B1 (en) * | 1994-02-01 | 2001-10-23 | Caphco, Inc. | Compositions and devices for controlled release of active ingredients |
US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US20020015957A1 (en) * | 2000-04-29 | 2002-02-07 | Hageman Gregory S. | Diagnostics and therapeutics for macular degeneration-related disorders |
US6350442B2 (en) * | 1999-04-13 | 2002-02-26 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
US6413536B1 (en) * | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
US6440942B1 (en) * | 2000-12-22 | 2002-08-27 | Enanta Pharmaceuticals, Inc. | 14-membered macrolides derived from leucomycins |
US6462026B1 (en) * | 2001-02-16 | 2002-10-08 | Enanta Pharmaceuticals, Inc. | Bicyclic leucomycins |
US6462071B1 (en) * | 2000-03-02 | 2002-10-08 | Vitreo-Retinal Technologies, Inc. | Agents for intravitreal administration to treat or prevent disorders of the eye |
US6482799B1 (en) * | 1999-05-25 | 2002-11-19 | The Regents Of The University Of California | Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial |
US6489335B2 (en) * | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
US20020187998A1 (en) * | 2001-04-12 | 2002-12-12 | Sucampo Ag | Local ophthalmic agent for treatment of ocular inflammation |
US20030018044A1 (en) * | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
US20030044452A1 (en) * | 2001-07-06 | 2003-03-06 | Sucampo Ag | Composition for topical administration |
US6534693B2 (en) * | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
US20030069232A1 (en) * | 1999-10-22 | 2003-04-10 | Chiou George C.Y. | Topical treatment of ocular hypertension, glaucoma, ischemic retinopathy and age-related macular degeneration with ophthalmic formulation of dopamine antagonists |
US20030130301A1 (en) * | 1999-04-30 | 2003-07-10 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
US6596296B1 (en) * | 1999-08-06 | 2003-07-22 | Board Of Regents, The University Of Texas System | Drug releasing biodegradable fiber implant |
US6613355B2 (en) * | 2000-05-11 | 2003-09-02 | A.P. Pharma, Inc. | Semi-solid delivery vehicle and pharmaceutical compositions |
US6617345B1 (en) * | 1996-02-13 | 2003-09-09 | G.D. Searle & Co. | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin |
US6667371B2 (en) * | 2001-11-16 | 2003-12-23 | A.P. Pharma, Inc. | Block copolymers based on poly(ortho esters) containing amine groups |
US6670398B2 (en) * | 1997-05-14 | 2003-12-30 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
US6673807B1 (en) * | 1998-04-06 | 2004-01-06 | Fujisawa Pharmaceutical Co., Ltd. | Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins |
US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
US20040092435A1 (en) * | 2002-11-07 | 2004-05-13 | Peyman Gholam A. | Treatment of ocular disease |
US20040198763A1 (en) * | 2003-01-16 | 2004-10-07 | Sucampo Ag | Method of treating dry eye with a macrolide compound |
US20050025810A1 (en) * | 2003-07-31 | 2005-02-03 | Gholam Peyman | Treatment of ocular disease |
US20050063996A1 (en) * | 2003-09-19 | 2005-03-24 | Gholam Peyman | Ocular solutions |
US20050063997A1 (en) * | 2003-09-19 | 2005-03-24 | Gholam Peyman | Ocular solutions |
US20050064010A1 (en) * | 2003-09-18 | 2005-03-24 | Cooper Eugene R. | Transscleral delivery |
US20050070468A1 (en) * | 2001-11-21 | 2005-03-31 | Sucampo Ag | Use of fk506 and analogues for treating allergic diseases |
US7008979B2 (en) * | 2002-04-30 | 2006-03-07 | Hydromer, Inc. | Coating composition for multiple hydrophilic applications |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2577049B2 (en) | 1987-06-04 | 1997-01-29 | 三共株式会社 | Cyclosporine preparation |
EP0313847A3 (en) * | 1987-10-01 | 1989-11-29 | G.D. Searle & Co. | Non-peptidyl alpha-succinamidoacyl aminodiols as anti-hypertensive agents |
JPH0710752A (en) | 1993-06-23 | 1995-01-13 | Tokushu Meneki Kenkyusho:Kk | Novel medicinal composition for treating allergic and autoimmune diseases |
US5429460A (en) * | 1994-03-09 | 1995-07-04 | Campian; Jonathon | Machine for cutting a workpiece made of styrofoam or like material |
JPH0930966A (en) | 1995-07-24 | 1997-02-04 | Gakuzo Tamura | New pharmaceutical preparation for eye |
JPH09315954A (en) | 1996-05-30 | 1997-12-09 | Kita:Kk | Medicine for preventing opacity of ocular tissue after ophthalmic operation |
JPH10218787A (en) | 1997-02-06 | 1998-08-18 | Akio Okamoto | Ophthalmic composition based on neurotrophic factor |
AR043071A1 (en) * | 1997-10-31 | 2005-07-20 | Abbott Lab | USE OF MACROLIDES FOR THE TREATMENT OF CANCER AND MACULAR DEGENERATION AND A PHARMACEUTICAL COMPOSITION |
CZ287497B6 (en) | 1997-12-30 | 2000-12-13 | Galena, A. S. | Topic eye preparations containing immunosuppressive substances |
DE69907418T2 (en) | 1998-02-23 | 2003-11-13 | Fujisawa Pharmaceutical Co | USE OF MACROLIDES FOR TREATING GLAUCOMA |
DE19810655A1 (en) | 1998-03-12 | 1999-09-16 | Univ Eberhard Karls | Pharmaceutical composition containing cyclosporin A suitable for topical administration for treating disorders of skin, mucosa and eyes |
DE69936195T2 (en) | 1998-04-27 | 2007-09-13 | Astellas Pharma Inc. | PHARMACEUTICAL GEL FORMULATION CONTAINING A TRICYCLIC SUBSTANCE (FK-506 / TACROLIMUS) |
US6864232B1 (en) * | 1998-12-24 | 2005-03-08 | Sucampo Ag | Agent for treating visual cell function disorder |
US6506206B1 (en) * | 1998-12-31 | 2003-01-14 | Depuy Orthopaedics, Inc. | Gel tourniquet cuff |
MXPA01010988A (en) | 1999-04-30 | 2004-04-21 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye. |
JP2001064198A (en) | 1999-08-24 | 2001-03-13 | Teika Seiyaku Kk | Therapeutic agent for corneal disease |
DK1142566T3 (en) | 2000-04-07 | 2004-02-09 | Medidom Lab | Ophthalmological formulations based on cyclosporine, hyaluronic acid and polysorbate |
CN1127955C (en) | 2000-07-07 | 2003-11-19 | 中山医科大学中山眼科中心 | Medicine for treating immune relative disease of anterior chamber and surface of eye |
CN1204919C (en) | 2000-08-30 | 2005-06-08 | 中国科学院化学研究所 | Long-acting intra-ocular release system of cyclosporin |
AU2001292881A1 (en) | 2000-09-20 | 2002-04-02 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
US6436906B1 (en) * | 2001-04-02 | 2002-08-20 | Enanta Pharmaceuticals, Inc. | 9-amino-14-membered macrolides derived from leucomycins |
AU2002245996B8 (en) | 2001-04-20 | 2005-07-14 | Ophthalmopharma Ag | Modified cyclosporine which can be used as a pro-drug and use thereof |
AR035293A1 (en) | 2001-08-23 | 2004-05-05 | Novartis Ag | OPHTHALMIC COMPOSITION. |
EP1455810B1 (en) | 2001-12-14 | 2007-06-13 | Jagotec Ag | Pharmaceutical formulation comprising cyclosporin and use thereof |
CN1456350A (en) | 2002-05-10 | 2003-11-19 | 刘继东 | Eye cyclosporin gel |
CA2495103A1 (en) | 2002-08-09 | 2004-02-19 | Sucampo Pharmaceuticals, Inc. | Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases |
EP1539157B1 (en) | 2002-09-18 | 2013-08-21 | Trustees Of The University Of Pennsylvania | Rapamycin for use in inhibiting or preventing choroidal neovascularization |
WO2004096261A1 (en) | 2003-05-02 | 2004-11-11 | Arturo Jimenez Bayardo | Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution |
-
2003
- 2003-09-19 US US10/667,161 patent/US7087237B2/en not_active Expired - Fee Related
-
2004
- 2004-09-16 CA CA002539472A patent/CA2539472A1/en not_active Abandoned
- 2004-09-16 WO PCT/US2004/030186 patent/WO2005030205A1/en active Application Filing
- 2004-09-16 AU AU2004275703A patent/AU2004275703A1/en not_active Abandoned
- 2004-09-16 JP JP2006526991A patent/JP2007505906A/en active Pending
- 2004-09-16 EP EP04784144A patent/EP1670465A1/en active Pending
-
2006
- 2006-06-12 US US11/451,100 patent/US20060228394A1/en not_active Abandoned
- 2006-06-12 US US11/451,052 patent/US20060228393A1/en not_active Abandoned
Patent Citations (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4093709A (en) * | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
US4131648A (en) * | 1975-01-28 | 1978-12-26 | Alza Corporation | Structured orthoester and orthocarbonate drug delivery devices |
US4138344A (en) * | 1975-01-28 | 1979-02-06 | Alza Corporation | Erodible agent releasing device comprising poly(orthoesters) and poly(orthocarbonates) |
US4180646A (en) * | 1975-01-28 | 1979-12-25 | Alza Corporation | Novel orthoester polymers and orthocarbonate polymers |
US4079038A (en) * | 1976-03-05 | 1978-03-14 | Alza Corporation | Poly(carbonates) |
US4304767A (en) * | 1980-05-15 | 1981-12-08 | Sri International | Polymers of di- (and higher functionality) ketene acetals and polyols |
US5411952A (en) * | 1987-09-03 | 1995-05-02 | University Of Georgia Research Foundation, Inc. | Ocular cyclosporine composition |
US4946931A (en) * | 1989-06-14 | 1990-08-07 | Pharmaceutical Delivery Systems, Inc. | Polymers containing carboxy-ortho ester and ortho ester linkages |
US5770607A (en) * | 1989-07-05 | 1998-06-23 | Fujisawa Pharmaceutical Co., Ltd. | Aqueous liquid composition for external use |
US5294604A (en) * | 1989-12-20 | 1994-03-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating ocular diseases by periocular administration of cyclosporine A or G |
US5387335A (en) * | 1990-11-21 | 1995-02-07 | Iwai; Isamu | Filter circulating type sewage disposal apparatus |
US5387589A (en) * | 1991-07-25 | 1995-02-07 | University Of Louisville Research Foundation, Inc. | Method of treating ocular inflammation |
US6306422B1 (en) * | 1994-02-01 | 2001-10-23 | Caphco, Inc. | Compositions and devices for controlled release of active ingredients |
US5457182A (en) * | 1994-02-15 | 1995-10-10 | Merck & Co., Inc. | FK-506 cytosolic binding protein, FKBP12.6 |
US6179817B1 (en) * | 1995-02-22 | 2001-01-30 | Boston Scientific Corporation | Hybrid coating for medical devices |
US6413536B1 (en) * | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
US5968543A (en) * | 1996-01-05 | 1999-10-19 | Advanced Polymer Systems, Inc. | Polymers with controlled physical state and bioerodibility |
US6238799B1 (en) * | 1996-02-09 | 2001-05-29 | Surface Solutions Laboratories, Inc. | Articles prepared from water-based hydrophilic coating compositions |
US6617345B1 (en) * | 1996-02-13 | 2003-09-09 | G.D. Searle & Co. | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin |
US5952371A (en) * | 1996-10-16 | 1999-09-14 | Merck & Co., Inc. | Triterpene derivatives with immunosuppressant activity |
US6258856B1 (en) * | 1996-12-19 | 2001-07-10 | The University Of Sydney | Method for preventing or controlling cataract |
US6670398B2 (en) * | 1997-05-14 | 2003-12-30 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
US6004565A (en) * | 1997-09-02 | 1999-12-21 | Yoshitomi Pharmaceutical Industries, Ltd. | Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties |
US6673807B1 (en) * | 1998-04-06 | 2004-01-06 | Fujisawa Pharmaceutical Co., Ltd. | Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins |
US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
US6350442B2 (en) * | 1999-04-13 | 2002-02-26 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
US6872383B2 (en) * | 1999-04-30 | 2005-03-29 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
US20030130301A1 (en) * | 1999-04-30 | 2003-07-10 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
US6482799B1 (en) * | 1999-05-25 | 2002-11-19 | The Regents Of The University Of California | Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial |
US6596296B1 (en) * | 1999-08-06 | 2003-07-22 | Board Of Regents, The University Of Texas System | Drug releasing biodegradable fiber implant |
US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US20030069232A1 (en) * | 1999-10-22 | 2003-04-10 | Chiou George C.Y. | Topical treatment of ocular hypertension, glaucoma, ischemic retinopathy and age-related macular degeneration with ophthalmic formulation of dopamine antagonists |
US6489335B2 (en) * | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
US20030018044A1 (en) * | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
US6462071B1 (en) * | 2000-03-02 | 2002-10-08 | Vitreo-Retinal Technologies, Inc. | Agents for intravitreal administration to treat or prevent disorders of the eye |
US20020015957A1 (en) * | 2000-04-29 | 2002-02-07 | Hageman Gregory S. | Diagnostics and therapeutics for macular degeneration-related disorders |
US6613355B2 (en) * | 2000-05-11 | 2003-09-02 | A.P. Pharma, Inc. | Semi-solid delivery vehicle and pharmaceutical compositions |
US6534693B2 (en) * | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
US6440942B1 (en) * | 2000-12-22 | 2002-08-27 | Enanta Pharmaceuticals, Inc. | 14-membered macrolides derived from leucomycins |
US6462026B1 (en) * | 2001-02-16 | 2002-10-08 | Enanta Pharmaceuticals, Inc. | Bicyclic leucomycins |
US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
US20020187998A1 (en) * | 2001-04-12 | 2002-12-12 | Sucampo Ag | Local ophthalmic agent for treatment of ocular inflammation |
US20030044452A1 (en) * | 2001-07-06 | 2003-03-06 | Sucampo Ag | Composition for topical administration |
US6667371B2 (en) * | 2001-11-16 | 2003-12-23 | A.P. Pharma, Inc. | Block copolymers based on poly(ortho esters) containing amine groups |
US20050070468A1 (en) * | 2001-11-21 | 2005-03-31 | Sucampo Ag | Use of fk506 and analogues for treating allergic diseases |
US7008979B2 (en) * | 2002-04-30 | 2006-03-07 | Hydromer, Inc. | Coating composition for multiple hydrophilic applications |
US20040092435A1 (en) * | 2002-11-07 | 2004-05-13 | Peyman Gholam A. | Treatment of ocular disease |
US20040198763A1 (en) * | 2003-01-16 | 2004-10-07 | Sucampo Ag | Method of treating dry eye with a macrolide compound |
US20050025810A1 (en) * | 2003-07-31 | 2005-02-03 | Gholam Peyman | Treatment of ocular disease |
US20050064010A1 (en) * | 2003-09-18 | 2005-03-24 | Cooper Eugene R. | Transscleral delivery |
US20050063997A1 (en) * | 2003-09-19 | 2005-03-24 | Gholam Peyman | Ocular solutions |
US20050063996A1 (en) * | 2003-09-19 | 2005-03-24 | Gholam Peyman | Ocular solutions |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9387165B2 (en) | 2005-02-09 | 2016-07-12 | Santen Pharmaceutical Co., Ltd. | Rapamycin formulations and methods of their use |
US9381153B2 (en) | 2005-02-09 | 2016-07-05 | Santen Pharmaceutical Co., Ltd. | Liquid formulations for treatment of diseases or conditions |
US8927005B2 (en) | 2005-02-09 | 2015-01-06 | Santen Pharmaceutical Co., Ltd. | Liquid formulations for treatment of diseases or conditions |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
US8637070B2 (en) | 2005-02-09 | 2014-01-28 | Santen Pharmaceutical Co., Ltd. | Rapamycin formulations and methods of their use |
US8367097B2 (en) | 2005-02-09 | 2013-02-05 | Santen Pharmaceutical Co., Ltd. | Liquid formulations for treatment of diseases or conditions |
US8658667B2 (en) | 2006-02-09 | 2014-02-25 | Santen Pharmaceutical Co., Ltd. | Stable formulations, and methods of their preparation and use |
US8492400B2 (en) | 2006-02-09 | 2013-07-23 | Santen Pharmaceutical Co., Ltd. | Stable formulations, and methods of their preparation and use |
US8486960B2 (en) | 2006-03-23 | 2013-07-16 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
US9452156B2 (en) | 2006-03-23 | 2016-09-27 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
US8222271B2 (en) | 2006-03-23 | 2012-07-17 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
US20090156881A1 (en) * | 2007-10-15 | 2009-06-18 | Stokes John P | Convergent well irradiating plaque for choroidal melanoma |
US9421241B2 (en) | 2008-05-07 | 2016-08-23 | The Regents Of The University Of California | Therapeutic modulation of ocular surface lubrication |
US9585936B2 (en) | 2008-05-07 | 2017-03-07 | The Regents Of The University Of California | Method for therapeutic replenishment and enrichment of ocular surface lubrication |
US8506944B2 (en) | 2008-05-07 | 2013-08-13 | The Regents Of The University Of California | Replenishment and enrichment of ocular surface lubrication |
US8551467B2 (en) | 2008-05-07 | 2013-10-08 | The Regents Of The University Of California | Replenishment and enrichment of ocular surface lubrication |
US8563028B2 (en) * | 2008-05-07 | 2013-10-22 | The Regents Of The University Of California | Ophthalmic device, and method of use thereof, for increasing ocular boundary lubrication |
US9730978B2 (en) | 2008-05-07 | 2017-08-15 | Thc Regents of the University of California | Compositions for treating dry eye disease |
US20110142908A1 (en) * | 2008-05-07 | 2011-06-16 | The Regents Of The University Of California | Ophthalmic Device, and Method of Use Thereof, for Increasing Ocular Boundary Lubrication |
US20110070222A1 (en) * | 2008-05-07 | 2011-03-24 | The Regents Of The University Of California | Therapeutic Modulation of Ocular Surface Lubrication |
US20140099343A1 (en) * | 2008-05-07 | 2014-04-10 | Schepens Eye Research Institute | Ophthalmic Device, and Method of Use Thereof, for Increasing Ocular Boundary Lubrication |
US9393285B2 (en) | 2008-05-07 | 2016-07-19 | The Regents Of The University Of California | Compositions for treating dry eye disease |
US20110059902A1 (en) * | 2008-05-07 | 2011-03-10 | The Regents Of The University Of California | Therapeutic Replenishment and Enrichment of Ocular Surface Lubrication |
US8945604B2 (en) * | 2008-05-07 | 2015-02-03 | The Regents Of The University Of California | Ophthalmic device, and method of use thereof, for increasing ocular boundary lubrication |
US20100092452A1 (en) * | 2008-05-07 | 2010-04-15 | The Regents Of The University Of California | Replenishment and Enrichment of Ocular Surface Lubrication |
US9138457B2 (en) | 2008-05-07 | 2015-09-22 | The Regents Of The University Of California | Therapeutic modulation of ocular surface lubrication |
US9248161B2 (en) | 2008-05-07 | 2016-02-02 | The Regents Of The University Of California | Method for therapeutic replenishment and enrichment of ocular surface lubrication |
US20100010082A1 (en) * | 2008-07-09 | 2010-01-14 | Aspreva International Ltd. | Formulations for treating eye disorders |
US8349806B2 (en) | 2008-07-10 | 2013-01-08 | Inspire Pharmaceuticals, Inc. | Method of treating blepharitis |
US20100022465A1 (en) * | 2008-07-10 | 2010-01-28 | Brubaker Kurt E | Method of treating blepharitis |
US20100190734A1 (en) * | 2009-01-23 | 2010-07-29 | Romulus Kimbro Brazzell | Method of treating dry eye disease with azithromycin |
US8106111B2 (en) | 2009-05-15 | 2012-01-31 | Eastman Chemical Company | Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions |
US10172789B2 (en) | 2013-01-24 | 2019-01-08 | Palvella Therapeutics Llc | Compositions for transdermal delivery of mTOR inhibitors |
US9044508B2 (en) | 2013-03-15 | 2015-06-02 | Insite Vision Corporation | Concentrated aqueous azalide formulations |
WO2014150067A1 (en) * | 2013-03-15 | 2014-09-25 | Insite Vision Incorporated | Concentrated aqueous azalide formulations |
US10722499B2 (en) | 2017-01-06 | 2020-07-28 | Palvella Therapeutics, Inc. | Anyhydrous compositions of mTOR inhibitors and methods of use |
US11135204B2 (en) | 2017-01-06 | 2021-10-05 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
WO2018220444A3 (en) * | 2017-05-30 | 2019-02-28 | Eximore Ltd. | Compositions and methods for treating dry eye syndrome delivering antibiotic macrolide |
CN111278401A (en) * | 2017-05-30 | 2020-06-12 | 艾克思摩尔有限公司 | Compositions and methods for delivering antibiotic macrolides for treatment of dry eye syndrome |
US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
US11679101B2 (en) | 2018-07-02 | 2023-06-20 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
Also Published As
Publication number | Publication date |
---|---|
WO2005030205A1 (en) | 2005-04-07 |
CA2539472A1 (en) | 2005-04-07 |
JP2007505906A (en) | 2007-03-15 |
US7087237B2 (en) | 2006-08-08 |
US20050063996A1 (en) | 2005-03-24 |
EP1670465A1 (en) | 2006-06-21 |
AU2004275703A1 (en) | 2005-04-07 |
US20060228393A1 (en) | 2006-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7083803B2 (en) | Ocular solutions | |
US7087237B2 (en) | Ocular solutions | |
US20050181018A1 (en) | Ocular drug delivery | |
US7083802B2 (en) | Treatment of ocular disease | |
US6489335B2 (en) | Treatment of ocular disease | |
US20030018044A1 (en) | Treatment of ocular disease | |
JP5696121B2 (en) | Biodegradable intraocular implant containing α-2 adrenergic receptor agonist | |
EP2197461B1 (en) | Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors | |
EP0863729B1 (en) | Implantable controlled release device to deliver drugs directly to an internal portion of the body | |
JP2007518690A6 (en) | Eye disease treatment | |
US20040092435A1 (en) | Treatment of ocular disease | |
RU2737893C2 (en) | Pegylated lipid nanoparticle with a bioactive lipophilic compound | |
Jervis | A summary of recent advances in ocular inserts and implants | |
Eperon et al. | A biodegradable drug delivery system for the treatment of postoperative inflammation | |
Soni et al. | Design and evaluation of ophthalmic delivery formulations | |
JP2022180505A (en) | Ophthalmic pharmaceutical composition, ophthalmic kit, and medical application thereof | |
Conway | Recent patents on ocular drug delivery systems | |
Castro-Balado et al. | New ophthalmic drug delivery systems | |
CA2830555A1 (en) | Intraocular drug delivery device and associated methods | |
Pignatello et al. | Nanotechnology in ophthalmic drug delivery: a survey of recent developments and patenting activity | |
Nayak et al. | Recent advances in ocular drug delivery systems | |
JAYATHEERTHA | SYSTEMATIC DEVELOPMENT AND EVALUATION OF PRONIOSOMAL GEL-DERIVED NIOSOMES FOR OCULAR DELIVERY OF SELECTED ANTI-GLAUCOMA DRUGS: AN IN VITRO, EX-VIVO AND IN-VIVO STUDY | |
WO2021137229A1 (en) | Compositions, kits and methods for enhancing therapeutic compliance | |
AU2019204106A1 (en) | Intraocular drug delivery device and associated methods | |
Wnek et al. | Ocular Implants for Drug Delivery/Susan S. Lee, Peng Yuan, Michael R. Robinson |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MINU, LLC, NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ADVANCED OCULAR SYSTEMS LIMITED;REEL/FRAME:020514/0039 Effective date: 20080207 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |